FLUAD Drug Profile

Summary for Tradename: FLUAD

High Confidence Patents:	19
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLUAD Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLUAD Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,376,652	2037-02-24	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	11,097,063	2039-01-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FLUAD Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	11,013,795	2036-06-24	Patent claims search
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	9,821,051	2031-10-21	Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510	11,013,795	2036-06-24	Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510	9,821,051	2031-10-21	Patent claims search

International Patents for FLUAD

Country	Patent Number	Estimated Expiration
Australia	2006207744
Australia	2005298946
Poland	1909871
Japan	2008528071

Supplementary Protection Certificates for FLUAD

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300880	Netherlands		PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
2017C/024	Belgium		PRODUCT NAME: SNELWERKENDE INSULINE ASPART; AUTHORISATION NUMBER AND DATE: EU/1/16/1160 20170111
132017000073676	Italy		PRODUCT NAME: INSULINA ASPART A RAPIDA AZIONE(FIASP); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1160, 20170111
122017000040	Germany		PRODUCT NAME: SCHNELL-WIRKENDES INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109

Market Dynamics and Financial Trajectory for the Biologic Drug FLUAD

Last updated: September 29, 2025

Introduction

FLUAD, a flagship influenza vaccine developed by Seqirus, a division of CSL Limited, represents a significant player within the vaccine industry. Known for its adjuvanted formulation, FLUAD targets elderly populations, aiming to bolster immunity against seasonal influenza. Given the rising global focus on immunization and the aging demographic, understanding the market dynamics and financial trajectory of FLUAD is crucial for stakeholders, pharmaceutical companies, and investors. This analysis explores current market trends, competitive positioning, regulatory landscape, and financial outlook shaping FLUAD's future.

Market Overview and Industry Context

The global influenza vaccine market was valued at approximately USD 4.9 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 7% through 2030 [1]. This growth stems from increased health awareness, expanding elderly populations, and the pandemic-driven emphasis on immunization strategies. Within this space, enhanced vaccines like FLUAD, distinguished by the use of adjuvants, are strategically positioned to capitalize on the need for higher efficacy in vulnerable age groups.

Key drivers of market expansion include:

• Aging demographic: The World Health Organization estimates that by 2050, nearly 16% of the global population will be over 65, an age group with heightened influenza risk.
• Influenza burden: Seasonal influenza causes significant morbidity and mortality, necessitating improved vaccines.
• COVID-19 impact: The pandemic has heightened awareness of viral vaccines, expanding acceptance and funding for influenza immunization programs.

Product Positioning of FLUAD

FLUAD is distinguished in the vaccine sector by its use of MF59, an oil-in-water adjuvant that enhances immune response in older adults, a group often exhibiting weaker immune reactions to standard vaccines [2]. This targeted approach grants FLUAD a competitive advantage in elderly immunization programs, especially in markets with active government support.

Clinical and regulatory milestones include:

• FDA approval (2015) for adults over 65.
• Regulatory approvals in multiple markets, including Europe, Japan, and Australia.
• Ongoing clinical trials assessing efficacy against emerging influenza strains and potential expansion into pediatric populations.

Competitive Landscape

The influenza vaccine market features dominant players such as Sanofi Pasteur, GSK, Abbott, and Seqirus. FLUAD’s unique adjuvanted formulation positions it as the premium offering within this segment, particularly for elderly populations.

Competitive dynamics involve:

• Efficacy differentiation: Adjuvanted vaccines like FLUAD demonstrate increased seroprotection in seniors compared to standard-dose vaccines.
• Pricing strategies: Premium pricing is justified by clinical benefits, though price competition remains intense.
• Market penetration: Targeted marketing towards national immunization programs and high-risk populations amplifies market share.

Emerging competitors are developing next-generation vaccines, including cell-based and recombinant platforms, which could impact FLUAD’s market share long-term.

Regulatory and Public Health Influences

Regulatory agencies continuously evaluate influenza vaccines for safety, efficacy, andpidemics preparedness. The COVID-19 pandemic has accelerated vaccine approval pathways, enabling faster adoption of new formulations. Meanwhile, government procurement policies and vaccination mandates influence market penetration.

Key factors include:

• Reimbursement policies and funding allocations.
• Public health campaigns emphasizing influenza vaccination.
• Expansion of flu vaccination recommendations for broader populations.

Financial Trajectory and Revenue Potential

Seqirus’s global strategy emphasizes expanding FLUAD's footprint, leveraging pandemic-driven awareness and expanding immunization programs. The revenue generated from FLUAD primarily stems from its use in developed markets like North America, Europe, and Australia, where influenza vaccination remains a public health priority.

Revenue Drivers:

• Market penetration: Increasing coverage in elderly populations via government-funded programs.
• Pricing strategies: Premium prices due to superior efficacy.
• Product portfolio expansion: Potential combination vaccines and new formulations.

Forecasting

Analysts project FLUAD’s revenue to grow at a CAGR of 5-8%, driven by increased immunization initiatives, demographic shifts, and ongoing clinical development. The vaccine's differential clinical profile supports premium pricing, contributing to higher profit margins.

Risks and Challenges:

• Competitive threats: Emerging vaccine technologies could erode market share.
• Regulatory hurdles: Delays in approval or changes in policies can impact sales.
• Supply chain disruptions: Manufacturing complexities for adjuvanted formulations could limit availability.

Market Opportunities and Future Outlook

The expanding global elderly demographic presents a substantial growth avenue for FLUAD. Additionally, innovations such as quadrivalent formulations, pre-pandemic stockpiling, and combination vaccines with COVID-19 antigens may significantly boost sales.

Emerging markets are also poised to adopt flu vaccines, especially as healthcare infrastructure advances and awareness surges. As a result, new licensing agreements and direct investments could further elevate FLUAD’s financial trajectory.

Conclusion

FLUAD’s market dynamics are shaped by demographic trends, clinical efficacy advantages, and strategic positioning within the influenza vaccine ecosystem. Its financial outlook appears robust, bolstered by aging populations and heightened health priorities post-pandemic. However, competition and innovation remain constant challenges. Stakeholders must monitor regulatory developments, market expansion strategies, and technological breakthroughs to capitalize on FLUAD's growth potential.

---

Key Takeaways

• FLUAD benefits from its adjuvanted formulation, positioning it as a preferred influenza vaccine for seniors.
• The global influenza vaccine market is projected to grow steadily, driven by demographic shifts and pandemic awareness.
• Strategic partnerships and expanded immunization programs will be vital for maximizing FLUAD's revenue potential.
• Competitors developing next-generation vaccines could challenge FLUAD’s market dominance.
• Ongoing clinical trials and regulatory streams present opportunities for product line expansion and enhanced market share.

---

FAQs

1. How does FLUAD differ from standard influenza vaccines?
FLUAD incorporates the MF59 adjuvant, enhancing immune response in older adults, thereby providing superior efficacy compared to non-adjuvanted vaccines, especially in populations over 65 [2].

2. What markets are the primary revenue sources for FLUAD?
The United States, Europe, and Australia are the main markets, due to their established immunization infrastructure and high elderly populations, with emerging opportunities in Asia and Latin America.

3. What role does regulatory approval play in FLUAD’s market expansion?
Regulatory approvals facilitate market entry and reimbursement, directly impacting sales. Expedited pathways, especially post-COVID-19, expedite availability in new markets.

4. How might emerging vaccine technologies impact FLUAD’s market share?
Next-generation vaccines, including recombinant and mRNA platforms, could substitute traditional vaccines, challenging FLUAD’s dominance unless ongoing clinical evidence supports comparable efficacy.

5. Are there prospects for FLUAD in pediatric populations?
Currently approved for adults over 65, clinical trials are exploring its safety and efficacy in other age groups, which could open additional revenue streams if successful.

---

Sources

[1] MarketsandMarkets, “Influenza Vaccines Market,” 2022.
[2] CDC, “Flu Vaccine Types,” 2023.